Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells

Oral Oncology

Volumn 39, Issue 1, 2003, Pages 49-55

  Mihara, Mariko ^a   Shintani, Satoru ^a   Nakashiro, Koh Ichi ^a   Hamakawa, Hiroyuki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; CDK inhibitor; Oral cancer

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; DNA FRAGMENT; FLAVOPIRIDOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN SUBUNIT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL DIVISION; CYCLIN-DEPENDENT KINASES; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GROWTH INHIBITORS; HUMANS; MOUTH NEOPLASMS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0037210732     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00019-2     Document Type: Article

References (30)

1. Pines J. Cyclins and cyclin-dependent kinases. a biochemical view Biochem. J. 308:1995;697-711.
2. Pines J. Cyclins and cyclin-dependent kinases. theme and variations Adv. Cancer Res. 66:1995;181-212.
3. Atherton-Fessler S., Parker L.L., Geahlen R.L., Piwnica-Worms H. Mechanisms of p34cdc2 regulation. Mol Cell Biol. 13(3):1993;1675-1685.
4. Solomon M.J., Lee T., Kirschner M.W. Role of phosphorylation in p34cdc2 activation. identification of an activating kinase Mol Biol Cell. 3(1):1992;13-27.
5. Desai D., Wessling H.C., Fisher R.P., Morgan D.O. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol. 15(1):1995;345-350.
6. Poon R.Y., Yamashita K., Howell M., Ershler M.A., Belyavsky A., Hunt T. Cell cycle regulation of the p34cdc2/p33cdk2-activating kinase p40MO15. J Cell Sci 107 ( Pt 10). 1994;2789-2799.
7. Matsuoka M., Kato J.Y., Fisher R.P., Morgan D.O., Sherr C.J. Nucleotide, protein activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol. 14(11):1994;7265-7275.
8. Gabrielli B.G., Lee M.S., Walker D.H., Piwnica-Worms H., Maller J.L. Cdc25 regulates the phosphorylation and activity of the Xenopus cdk2 protein kinase complex. J Biol Chem. 267(25):1992;18040-18046.
9. Gu Y., Rosenblatt J., Morgan D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11(11):1992;3995-4005.
10. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
11. Sedlacek H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M.et al. Flavopiridol (L86 8275;NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 9:1996;1143-1168.
12. Jager W., Zembsch B., Wolschann P., Pittenauer E., Senderowicz A.M., Sausville E.A.et al. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 62:1998;1861-1873.
13. Senderowicz A.M., Headlee D., Stinson S.F., Lush R.M., Kalil N., Villalba L.et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 16:1998;2986-2999.
14. Carlson B.A., Pearlstein R.A., Naik R.G., Sedlacedk H.H., Sausville E.A., Worland P.J. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs. Proc Am Assoc Cancer Res. 37:1996;A2897.
15. Serizawa H., Makela T.P., Conaway J.W., Conaway R.C., Weinberg R.A., Young R.A. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature. 374(6519):1995;280-282.
16. Patel V., Senderowicz A.M., Pinto J.D., Igishi T., Raffeld M., Quintanilla-Martinez L.et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Investig. 102:1998;1674-1681.
17. Bible K.C., Kaufmann S.H. Flavopiridol. a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells Cancer Res. 56:1996;4856-4861.
18. Schrump D.S., Matthews W., Chen G.A., Mixon A., Altorki N.K. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 4:1998;2885-2890.
19. Chiarugi V., Magnelli L., Cinelli M., Basi G. Apoptosis and the cell cycle. Cell Mol Biol Res. 40:1994;603-612.
20. Mcdonnell T.J., Beham A., Sarkiss M., Andresen M., Lo P. Importance of the Bcl-2 family in cell death regulation. Experimentia (Basel). 52:1996;1008-1017.
21. Sellins K.S., Cohen J.J. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J. Immunol. 139:1987;3199-3206.
22. Byrd J.C., Shinn C., Waselenko J.K., Fuchs E.J., Lehman T.A., Nguyen P.L.et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 92:1998;3804-3816.
23. Li Y., Bhuiyan M., Mohammad R.M., Sarkar F.H. Induction of apoptosis in breast cancer cells by TPA. Oncogene. 17:1998;2915-2920.
24. Jia L.Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog. 19:1997;243-253.
25. Burns J.E., Baird M.C., Clark L.J., Burns P.A., Edington K., Chapman C.et al. Gene mutations and increased levels p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer. 67:1993;1274-1284.
26. Min B.M., Beak J.H., Shin K.H., Gujiluva C.N., Cherrick H.M., Park N.H. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell line. Eur J Cancer B Oral Oncol. 30B:1994;338-345.
27. Shapiro G.I., Koestner D.A., Matranga C.B., Rollins B.J. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 5(10):1999;2925-2938.
28. L is expressed in neuroblastoma cells and modulate chemotherapy-induced apoptosis. Cancer Res. 55:1995;2576-2582.
29. Miyashita T., Krajewski S., Krajewski M., Wang H.G., Lin H.K., Liebermann D.A.et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
30. S sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55:1995;2507-2510.